[Neurological aspect of the hyperactive urinary bladder syndrome].
Mazo
E B
EB
Krivoborodov
G G
GG
D001561:Benzilates; D001921:Brain / Q000098:blood supply; D001927:Brain Diseases / Q000453:epidemiology; D002560:Cerebrovascular Circulation / Q000502:physiology; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009662:Nortropanes / Q000627:therapeutic use; D010300:Parkinson Disease / Q000453:epidemiology; D049268:Positron-Emission Tomography; D011812:Quinuclidines / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*
D001561:Benzilates; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D009662:Nortropanes; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; C003330:trospium chloride; C005419:oxybutynin; D000069464:Solifenacin Succinate